title: [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
abstract: For younger patients with relapsed or refractory lymphomas who respond to salvage therapy, autologous stem cell trans- plantation(ASCT)is the standard of care. Recently, it was demonstrated that the gemcitabine/dexamethasone/cisplatin (GDP) regimen for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) prior to ASCT was not inferior to the standard dexamethasone/cytarabine/cisplatin (DHAP) regimen for patients with relapsed and refractory aggressive lymphoma. In Japan, most patients who receive CDDP-containing regimens are hospitalized because of the substantial transfusions required for preventing renal dysfunction. We initiated GDP therapy combined with a short period of hydration and the administration of a magnesium agent and mannitol for 5 patients with relapsed and refractory aggressive lymphoma. In 4 cases, GDP was safely administered on an outpatient basis. Furthermore, peripheral blood stem cells were successfully collected in 2 patients. After stem cell harvest, ASCT was performed in a patient with diffuse large B-cell lymphoma, with the patient remaining in complete remission (CR) after ASCT.
authors.affiliation: Dept. of Hematology, Juntendo University School of Medicine.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Aota
authors.forename: Masaru
authors.initials: M
authors.lastname: Tanaka
authors.forename: Naoki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Jyunichi
authors.initials: J
authors.lastname: Tomomatu
authors.forename: Akihiko
authors.initials: A
authors.lastname: Gotoh
authors.forename: Norio
authors.initials: N
authors.lastname: Komatu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D012008:Recurrence; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D003907:Dexamethasone; D002945:Cisplatin; D000093542:Gemcitabine